Physician profile
Sara M Graham
NPI 1548869191
$2,532.99
in general payments reported to CMS, 2019-2025
21 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $309 · 2023: $684 · 2024: $534 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.83 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $444.58 | 2022-2025 | Lifevest |
| Pfizer INC. | $370.92 | 2023-2025 | |
| Amgen INC. | $341.61 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $326.26 | 2022-2025 | Watchman Access System, Watchman |
| Novo Nordisk INC | $140.29 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $132.50 | 2023-2025 | |
| Teleflex LLC | $125.70 | 2023 | Urolift |
| Kiniksa Pharmaceuticals, LTD. | $95.83 | 2022-2023 | Arcalyst |
| Bridgebio Pharma, INC. | $89.44 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $67.97 | 2022-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $63.44 | 2023-2025 | Wainua, Farxiga, Andexxa |
| Daiichi Sankyo INC. | $52.29 | 2022-2023 | Injectafer |
| Lilly USA, LLC | $50.85 | 2025 | Mounjaro, Zepbound |
| Kestra Medical Technology Services, INC. | $36.83 | 2022-2023 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $35.15 | 2023-2025 | Kerendia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $35.03 | 2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $34.90 | 2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.48 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $21.63 | 2022 | |
| Heartflow, INC. | $20.48 | 2025 | |
| Esperion Therapeutics, INC. | $12.81 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.